EA201891732A1 - BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR - Google Patents
BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDRInfo
- Publication number
- EA201891732A1 EA201891732A1 EA201891732A EA201891732A EA201891732A1 EA 201891732 A1 EA201891732 A1 EA 201891732A1 EA 201891732 A EA201891732 A EA 201891732A EA 201891732 A EA201891732 A EA 201891732A EA 201891732 A1 EA201891732 A1 EA 201891732A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- binding proteins
- bispecific binding
- kdr
- bispecific
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Предложены биспецифические связывающие белки, такие как биспецифические антитела, которые связываются и с PD-L1 человека, и с KDR человека. Указанные биспецифические связывающие белки эффективны для лечения заболеваний и состояний, характеризующихся иммуносупрессией и/или избыточным ангиогенезом.Bispecific binding proteins such as bispecific antibodies that bind to human PD-L1 and human KDR are proposed. These bispecific binding proteins are effective for the treatment of diseases and conditions characterized by immunosuppression and / or excessive angiogenesis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662290350P | 2016-02-02 | 2016-02-02 | |
PCT/US2017/016230 WO2017136562A2 (en) | 2016-02-02 | 2017-02-02 | Bispecific binding proteins for pd-l1 and kdr |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201891732A1 true EA201891732A1 (en) | 2019-02-28 |
Family
ID=59501012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891732A EA201891732A1 (en) | 2016-02-02 | 2017-02-02 | BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3411068A4 (en) |
JP (1) | JP2019506863A (en) |
CN (1) | CN109310755A (en) |
EA (1) | EA201891732A1 (en) |
WO (1) | WO2017136562A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA42971A (en) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF |
JP2020522486A (en) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | Activatable anti-PDL1 antibody and method of using the same |
JP7145895B2 (en) * | 2017-09-01 | 2022-10-03 | 四川科倫博泰生物医薬股▲フン▼有限公司 | recombinant bispecific antibody |
KR102469248B1 (en) * | 2018-02-28 | 2022-11-22 | 에이피 바이오사이언시스, 아이엔씨. | Bifunctional proteins with checkpoint inhibition for targeted therapy |
CN111196856A (en) * | 2018-11-19 | 2020-05-26 | 三生国健药业(上海)股份有限公司 | anti-HER 2/PD1 bispecific antibodies |
CN111196855B (en) * | 2018-11-19 | 2022-11-15 | 三生国健药业(上海)股份有限公司 | anti-EGFR/PD-1 bispecific antibodies |
US11407832B2 (en) | 2018-12-03 | 2022-08-09 | Immuneonco Biopharmaceuticals (Shanghai) Inc. | Recombinant protein targeting PD-L1 and VEGF |
CN109776683B (en) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | Bispecific antibody and preparation method and application thereof |
WO2020261093A1 (en) * | 2019-06-24 | 2020-12-30 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
CN110563849B (en) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | anti-VEGF-anti-PD 1 bispecific antibody |
CN110498857B (en) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | anti-VEGF-anti-PD 1 bispecific antibody |
AU2019461286B2 (en) * | 2019-08-09 | 2024-01-04 | Anhui Biox Vision Biological Technology Co., Ltd. | Anti-VEGF-anti-PD1 bispecific antibody with new-type structure |
CN110760517B (en) * | 2019-10-09 | 2022-04-29 | 天津大学 | Antagonistic PD-1 camel antibody analogue AP gene, protein and application |
CN113563473A (en) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | Tetravalent bispecific antibody, preparation method and application thereof |
CN113754772A (en) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | Bispecific antibody for resisting PDL1 XKDR |
CN113754773A (en) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | Bispecific antibody for resisting PD1 XPDL 1 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005051299A2 (en) * | 2003-11-19 | 2005-06-09 | Dyax Corp. | Metalloproteinase-binding proteins |
WO2008019061A2 (en) * | 2006-08-03 | 2008-02-14 | Vaccinex, Inc. | Anti-il-6 monoclonal antibodies and uses thereof |
US7935345B2 (en) * | 2007-05-21 | 2011-05-03 | Children's Hospital & Research Center At Oakland | Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use |
CA2819356C (en) * | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
ES2625818T3 (en) * | 2011-04-19 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Bispecific anti-IGF-1R and anti-ErbB3 antibodies |
HUE051954T2 (en) * | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
AU2013267267B2 (en) * | 2012-05-31 | 2017-10-26 | Genentech, Inc. | Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists |
EA201500362A1 (en) * | 2012-10-05 | 2015-08-31 | Кадмон Корпорейшн, Ллк | RHO-KINASE INHIBITORS |
EP2903645A2 (en) * | 2012-10-05 | 2015-08-12 | Kadmon Corporation, LLC | Treatment of ocular disorders |
WO2014209804A1 (en) * | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
US10519247B2 (en) * | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
CN113603788A (en) * | 2014-01-15 | 2021-11-05 | 卡德门企业有限公司 | Immunomodulator |
-
2017
- 2017-02-02 EA EA201891732A patent/EA201891732A1/en unknown
- 2017-02-02 WO PCT/US2017/016230 patent/WO2017136562A2/en active Application Filing
- 2017-02-02 JP JP2018540412A patent/JP2019506863A/en active Pending
- 2017-02-02 CN CN201780021304.8A patent/CN109310755A/en active Pending
- 2017-02-02 EP EP17748163.7A patent/EP3411068A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3411068A4 (en) | 2020-01-29 |
WO2017136562A3 (en) | 2017-09-28 |
CN109310755A (en) | 2019-02-05 |
WO2017136562A2 (en) | 2017-08-10 |
EP3411068A2 (en) | 2018-12-12 |
JP2019506863A (en) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891732A1 (en) | BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR | |
CY1123163T1 (en) | ANTIBODIES THAT BIND BETA KLOTHO REGION 2 AND METHODS OF USING THEM | |
EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
EA201890131A1 (en) | IMMUNOMODULATION AND TREATMENT OF SOLID TUMORS BY ANTIBODIES THAT SPECIFICALLY CONNECT CD38 | |
EA201892362A1 (en) | AGONISTIC ANTIBODIES THAT ARE BINDING HUMAN CD40, AND THEIR OPTIONS | |
EA201990912A1 (en) | ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS | |
EA201890145A1 (en) | ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | |
EA201890305A1 (en) | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | |
EA201791485A1 (en) | ANTI-CD47-ANTIBODIES AND THEIR APPLICATIONS | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
EA201890790A1 (en) | CONNECTING PD-1 PROTEINS AND METHODS OF THEIR APPLICATION | |
EA201890453A1 (en) | ANTI-ANGPTL8 ANTIBODIES AND THEIR APPLICATION | |
EA201991720A1 (en) | ANTIBODIES TO ALPHA-SINUCLEIN AND THEIR APPLICATIONS | |
EA201690167A1 (en) | HUMANIZED OR CHEMICAL ANTIBODIES TO CD3 | |
EA201891331A1 (en) | BIPARATOPE POLYPEPTIDES - ANTAGONISTS OF TRANSMISSION OF WNT SIGNAL IN TUMOR CELLS | |
GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
EA201790719A1 (en) | BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE TO BIND CD19 AND CD3, AND THEIR APPLICATION THEREOF | |
EA202190609A1 (en) | ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G | |
EA202091315A3 (en) | HUMAN ANTIBODIES BINDING G-PROTEIN RSV | |
EA201691541A1 (en) | NEW ANTI-BAFF ANTIBODIES | |
EA201892225A1 (en) | ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION | |
EA201991546A1 (en) | ANTIGEN-BINDING PROTEINS AGAINST NEUROPILIN AND WAYS OF THEIR APPLICATION | |
EA201792220A1 (en) | ANTIBODY-MEDIATED NEUTRALIZATION OF THE CHICUNG VIRUS VIRUS | |
EA201992460A1 (en) | BTLA ANTIBODY ANTIBODIES AND THEIR APPLICATION | |
EA201792561A1 (en) | ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION |